| dc.contributor.author | Sharma, Anand | |
| dc.contributor.author | Suleyman, Narin M. | |
| dc.contributor.author | Vasdev, Nikhil | |
| dc.contributor.author | Jones, Oliver | |
| dc.date.accessioned | 2023-09-06T10:45:01Z | |
| dc.date.available | 2023-09-06T10:45:01Z | |
| dc.date.issued | 2019 | |
| dc.identifier.citation | Sharma , A , Suleyman , N M , Vasdev , N & Jones , O 2019 , ' Immunotherapy in Urological Tumors ' , Reviews in Urology , vol. 21 , no. 1 , pp. 15–20 . | |
| dc.identifier.uri | http://hdl.handle.net/2299/26634 | |
| dc.description | © 2019 MedReviews. | |
| dc.description.abstract | The past decade has seen significant improvement in our understanding of tumor biological features, which has led to use of anti-programmed-death 1 (PD-1) and anti-PDligand-1 (PD-L1) agents and cytotoxic T lymphocytes antigen 4 (CTLA-4) inhibitors in a multitude of cancers. These immunotherapeutic agents have shown activity in melanoma, lung, head and neck, colorectal, urological, and other cancers. This article details the use of immunotherapy agents in urothelial, renal, prostate, and testicular tumors. | en |
| dc.format.extent | 6 | |
| dc.format.extent | 315161 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | Reviews in Urology | |
| dc.title | Immunotherapy in Urological Tumors | en |
| dc.contributor.institution | Centre for Health Services and Clinical Research | |
| dc.contributor.institution | Basic and Clinical Science Unit | |
| dc.contributor.institution | Extracellular Vesicle Research Unit | |
| dc.contributor.institution | School of Life and Medical Sciences | |
| dc.contributor.institution | Department of Clinical, Pharmaceutical and Biological Science | |
| dc.description.status | Peer reviewed | |
| dc.identifier.url | https://www.ncbi.nlm.nih.gov/pmc/issues/336832/ | |
| rioxxterms.type | Journal Article/Review | |
| herts.preservation.rarelyaccessed | true | |
